2025 Market SizeUSD 47.3 MnBase year
2026 EstimateUSD 48.66 MnEstimated year
2034 ForecastUSD 60.93 MnForecast value
CAGR2.9%2026–2034
Largest RegionNorth America2025
Breast Cancer Screening Tests Market Overview
The global breast cancer screening tests market was valued at USD 47.3 million in 2025 and is estimated at USD 48.66 million in 2026. It is projected to reach USD 60.93 million by 2034, advancing at a 2.9% CAGR during 2026–2034. North America represented the largest regional market in the 2025 base year.
2.43 millionGlobal breast cancer diagnoses estimated in 2024IARC, October 2026
40–74USPSTF recommended U.S. screening age rangeUSPSTF, April 2024
71.8%England programme coverage at 31 March 2025NHS England Digital
50–74Australian actively invited screening age rangeAustralian Government
Breast screening is principally a preventive imaging pathway, not a single laboratory assay. Routine mammography provides the baseline examination; digital breast tomosynthesis offers additional tissue planes, while ultrasound and magnetic resonance imaging supplement evaluation for selected risk profiles. Clinical breast examination, hereditary risk testing and interpretation software sit alongside imaging but have distinct clinical purposes. The publisher benchmark measures a narrowly defined basket of screening-test products and associated test-related revenues rather than the full value of mammography equipment, radiology service fees or nationwide screening programme budgets.
IARC estimated 2.43 million new breast cancer cases in 2024 and almost 700,000 deaths, maintaining pressure on national early-detection programmes. The United States Preventive Services Task Force recommends mammography every other year from age 40 through 74 for average-risk women. National rules differ: England routinely invites women aged 50 to 70 every three years, whereas Australia actively invites women aged 50–74 for biennial screening. These distinctions influence recurring testing volumes, provider procurement and the mix of routine and supplemental examinations.
The FDA began enforcing standardized breast-density notifications in September 2024 under revised mammography quality rules. Patients and clinicians now receive more consistent information about dense tissue, which can obscure lesions and alter risk discussions. Supplemental MRI and ultrasound are not universal substitutes for mammography, and evidence on screening benefits in average-risk women with dense breasts remains incomplete. Nevertheless, density communication creates demand for risk-stratification software, patient navigation, follow-up capacity and specialist imaging where clinical assessment supports additional testing.
Technology investment is moving toward shorter examinations, improved positioning and radiologist decision support. GE HealthCare highlighted Pristina Via and breast ultrasound at the 2025 Society of Breast Imaging meeting, while Siemens expanded MAMMOMAT B.brilliant functionality later that year. ScreenPoint Medical and iCAD are deploying software for lesion detection and workflow assistance, and Fujifilm installed AI-assisted mammography systems in India during 2025–2026. These developments affect the revenue mix within the defined testing basket without implying that the entire imaging hardware market is included.
Source: IARC global burden; USPSTF recommendation; FDA density notification; NHS programme statistics.
Key Takeaways: Breast Cancer Screening Tests Market
- Market value: The narrowly defined screening-test basket represented USD 47.3 million in 2025, distinct from the far larger global expenditure on mammography systems and imaging services.
- Growth forecast: Publisher endpoints support USD 48.66 million in 2026 and USD 60.93 million in 2034, corresponding to a 2.9% CAGR.
- Leading test type: Imaging Tests contributed a modeled 64% of 2025 revenue within the scoped basket, ahead of genetic, laboratory and physical examination products.
- Leading application: Hospitals accounted for a modeled 43% of 2025 test-related revenue, reflecting imaging capacity and specialist follow-up pathways.
- Largest regional market: North America represented a modeled 42% of the base-year market, supported by established reimbursement and dense-breast notification rules.
- Clinical demand: Routine screening eligibility, participation gaps and rising global cancer incidence support steady repeat-test volumes rather than explosive annual expansion.
- Supplier positioning: Hologic, GE HealthCare, Siemens Healthineers, Fujifilm, iCAD and ScreenPoint Medical compete across acquisition, workflow and software adjuncts.
- Coverage: Four mutually exclusive dimensions—Type, Application, End User and Screening Method—are analyzed across five regions and selected countries.
Report Scope & Market Segmentation
The assessment follows the publisher-defined screening-test revenue basket and separates clinical examination modality, care location, patient cohort and programme route to prevent overlap between analytical dimensions.
| Report Attribute | Coverage |
|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Imaging Tests; Genetic Tests; Laboratory Tests; Physical Examination Tests |
| By Application | Hospitals; Diagnostic Centers; Cancer Institutes; Research Laboratories |
| By End User | Women Aged 50–74; Women Aged 40–49; High-Risk Younger Cohorts; Other Eligible Participants |
| By Screening Method | Organized Population Screening; Opportunistic Screening; Risk-Directed Screening |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Germany; Spain; China; India; Japan; Australia; Brazil; United Arab Emirates |
| Key Market Players | Hologic, Inc.; GE HealthCare Technologies Inc.; Siemens Healthineers AG; FUJIFILM Holdings Corporation; Planmed Oy; ScreenPoint Medical B.V.; iCAD, Inc.; Myriad Genetics, Inc.; Koios Medical, Inc.; Koninklijke Philips N.V. |
Market Definition & Revenue Boundaries
Included revenue is limited to the screening-test categories defined by the publisher: mammography-linked tests and imaging adjuncts, eligible genetic risk panels, relevant laboratory screening products and paid physical examination test services. The reported USD 46 million 2024 publisher value is retained as a scoped market benchmark; it must not be interpreted as the worldwide sum of all mammography reimbursements, all breast imaging equipment sales, or the operating budgets of public screening systems. Full-system capital equipment, downstream cancer treatment, biopsies after a positive screen and unrelated multi-cancer testing are excluded.
The Type axis identifies the primary test billed or sold, with any accompanying AI interpretation assigned to the original modality rather than counted twice. Application classifies the facility delivering the test; End User classifies the eligible participant cohort; Screening Method describes how the person enters the programme. A single revenue transaction belongs to one category within each axis. Country shares are allocated by testing revenue rather than by cancer incidence, and the regional figures are scenario allocations rather than audited market-share disclosures.
Breast Cancer Screening Tests Market Dynamics
Drivers Impact Analysis*
| Market Drivers | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|
| Age-40 screening eligibility | High | +0.90% | High | High | Medium |
| Higher programme participation | Medium-High | +0.75% | High | High | Medium |
| Tomosynthesis and image quality | Medium | +0.55% | High | Medium | Medium |
| Risk-adapted supplemental pathways | Low-Medium | +0.45% | Medium | High | High |
| AI reading and workflow tools | Low | +0.35% | Medium | High | High |
| Others (screening infrastructure and outreach) | Low | +0.25% | Medium | Medium | Medium |
Restraints Impact Analysis*
| Market Restraints | Impact Rank | CAGR Contribution (%) | 2026–2028 | 2029–2031 | 2032–2034 |
|---|
| Limited public screening capacity | High | -0.15% | High | Medium | Medium |
| False positives and patient anxiety | Medium | -0.10% | Medium | Medium | Low |
| Others (cost, radiation concerns and access) | Low | -0.10% | Medium | Medium | Medium |
*CAGR contribution shows the percentage points each factor adds to or removes from the 2.9% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.
Broader age eligibility increases recurrent imaging demand
The USPSTF recommendation issued in April 2024 extends routine biennial screening to women aged 40–74, increasing the eligible population compared with older age-50 thresholds. CDC survey research found that 62.1% of U.S. women aged 40–49 had received mammography within two years in 2023, versus 80.0% of those aged 50–74. Closing that participation difference requires scheduling capacity, payer clarity and communication tailored to first-time participants. The commercial effect is gradual because changing guidance does not immediately expand scanner availability or eliminate the practical barriers facing women who work irregular hours.
National participation programmes support dependable repeat volumes
England screened 2.15 million women aged 45 and older during 2024–25 and detected 19,291 cancers through the programme. Coverage among eligible women reached 71.8% by March 2025, leaving a meaningful participation gap even in an established national system. Public invitations, reminders and mobile units can improve utilization without requiring a change in the underlying imaging modality. Vendors supplying positioning, image management and reading support benefit when existing sites increase throughput, while public purchasers continue to scrutinize cost per completed examination and subsequent recall burden.
Breast-density communication creates targeted adjunct demand
The FDA requires mammography facilities to provide breast-density information to patients and referring clinicians under rules enforced from September 2024. Dense tissue may make some cancers harder to see on conventional images, creating more discussions about personalized surveillance. MRI is recommended for many women with high inherited risk, while ultrasound and contrast-enhanced techniques may be considered according to local protocols and available evidence. The revenue opportunity is selective: routine supplemental imaging for all women with dense breasts is not a settled universal standard, and risk assessment must guide additional tests.
Specialist staffing and equipment budgets constrain access
Digital mammography relies on trained technologists, radiologists, maintained equipment and consistent quality assurance. These requirements make programme expansion difficult for rural communities and low-resource systems, even when awareness campaigns increase requests for appointments. England reported 73,451 referrals for diagnostic assessment during 2024–25, representing 3.4% of those screened, which illustrates the need for downstream capacity after a screening image. Capital procurement cycles, service contracts and radiologist availability can delay adoption of advanced tomosynthesis or supplemental MRI despite credible clinical advantages.
False-positive workups and communication remain adoption barriers
Screening can detect disease before symptoms appear, but it also generates recalls, additional imaging and occasionally biopsies that do not identify cancer. The NHS explicitly warns about overdiagnosis and false reassurance, while the USPSTF identifies uncertainty around several supplemental screening strategies. Anxiety and logistical costs can deter repeat participation, particularly where follow-up services are far from home. Better image reconstruction and decision support may reduce avoidable recalls, but clinical validation and local quality monitoring remain essential before workflow claims are converted into routine purchasing decisions.
Sources: USPSTF April 2024; CDC Preventing Chronic Disease 2025; FDA MQSA; NHS England Digital 2024–25; NHS screening guidance.
Market Trends & Growth Opportunities
Digital breast tomosynthesis advances routine acquisition
Tomosynthesis reconstructs thin breast slices to reduce tissue overlap, making it a valuable upgrade for sites seeking improved lesion visibility. Siemens Healthineers promotes five-second wide-angle acquisition with MAMMOMAT B.brilliant, while GE HealthCare expanded its Pristina platform with AI-supported reconstruction in November 2025. Planmed continues to supply Clarity systems with synthetic two-dimensional images, though specific versions are not cleared in every country. Purchasers weigh acquisition speed, radiation dose, reader preference and service cost together, rather than treating a higher slice count as sufficient proof of clinical benefit.
AI assistance moves into routine radiology worklists
ScreenPoint Medical reported a Spanish regional deployment covering roughly 15–17 screening centres in September 2025, while iCAD partnered with Koios Medical to combine mammography and breast-ultrasound decision support. These systems flag suspicious regions, estimate density or prioritize examinations for clinician review. Evidence from a ScreenPoint-supported reader study published in 2025 found improved area-under-curve performance without a statistically significant increase in reading time. Commercial adoption still depends on integration with picture-archiving systems, oversight of algorithm drift and transparent accountability for final interpretation.
Personalized risk assessment supplements age-based invitations
The American College of Radiology recommends risk assessment by age 25 and earlier MRI surveillance for selected high-risk women. Myriad Genetics expanded its MyRisk hereditary cancer panel to 63 genes in November 2025, supporting more comprehensive risk evaluation where clinically appropriate. Genetic testing does not replace mammography, and a pathogenic variant does not establish that cancer is present. The practical opportunity lies in identifying people who merit more intensive surveillance, coordinating appointments and ensuring that risk scores are interpreted within validated population and family-history contexts.
Mobile and regional installations widen geographic reach
Fujifilm installed AMULET Innovality at a diagnostic centre in Nizamabad in September 2025 and an AI-assisted AMULET SOPHINITY system in Mumbai in June 2026. These installations demonstrate demand beyond the largest hospital campuses, especially where private diagnostic chains are expanding preventive services. Compact system footprints, positioning aids and remote maintenance can help centres manage limited space and staffing. However, outreach programmes must also secure follow-up referral pathways; an isolated screening unit has limited public-health value if abnormal results cannot be investigated promptly.
Breast Cancer Screening Tests Market Segmentation by Type
Report SegmentationBy Type
The Type axis assigns revenue to the primary clinical test delivered. Imaging is the dominant entry point, while genetics identifies inherited susceptibility and laboratory methods remain selective adjuncts. A physical examination is not treated as equivalent to imaging sensitivity.
Largest test categoryImaging Tests
Imaging Tests accounted for a modeled 64% of 2025 revenue in the defined basket. Mammography forms the routine screening foundation, with digital tomosynthesis improving tissue separation and breast MRI used for selected high-risk women. Ultrasound is mainly a supplemental modality rather than a universal replacement for mammography.
Risk stratificationGenetic Tests
Genetic Tests represented a modeled 17% of revenue, covering validated hereditary-risk panels and related clinical interpretation rather than tests that diagnose a current tumour. Myriad Genetics broadened its MyRisk panel in 2025, reflecting demand for more comprehensive hereditary assessment. Uptake is constrained by eligibility criteria, counselling capacity and payer coverage for people without a strong personal or family history.
Selective screening adjunctLaboratory Tests
Laboratory Tests held a modeled 11% of the publisher-defined basket, reflecting selected blood-based or biomarker-linked products used in risk evaluation and research-supported screening pathways. No circulating biomarker has replaced mammography as the established population screening standard. Buyers therefore distinguish clinically validated risk tools from investigational assays and avoid treating every laboratory cancer test as a breast screening product.
Clinical access pointPhysical Examination Tests
Physical Examination Tests contributed a modeled 8%, concentrated in clinician encounters that lead to referral, education or risk evaluation. Palpation can identify symptoms but is not a stand-alone substitute for mammographic population screening in settings with access to imaging. The category has low unit revenue because examinations are often bundled into primary-care visits.
The Type split distinguishes the screening encounter from follow-up diagnostics, so a mammogram that prompts an ultrasound or biopsy is not automatically counted as multiple primary screening tests. Genetic risk results influence future surveillance intensity without being equated to a positive cancer diagnosis.
Breast Cancer Screening Tests Market Segmentation by Application
Report SegmentationBy Application
Application classifies the location delivering the paid test rather than the patient demographic. Hospitals and outpatient diagnostic centres capture most activity, with cancer institutes and research laboratories supporting specialist protocols and validation.
Largest clinical settingHospitals
Hospitals accounted for a modeled 43% of 2025 screening-test revenue, supported by integrated breast clinics, radiology departments and referral services. Large hospital systems can combine mammography with contrast imaging, MRI and multidisciplinary assessment when a screening result is indeterminate. Hospitals retain substantial share because high-risk patients need coordinated services that smaller centres may lack.
Convenient outpatient accessDiagnostic Centers
Diagnostic Centers generated a modeled 35% share and compete through appointment availability, accessible locations and standardized reporting. Fujifilm installations in Indian outpatient facilities illustrate how private providers can extend screening technology into secondary cities and urban neighbourhoods. Diagnostic chains are more likely to prioritize compact mammography systems, efficient patient turnover and predictable service contracts. Their growth depends on reimbursement, referral relationships and maintaining quality oversight across geographically dispersed sites.
Specialist high-risk programmesCancer Institutes
Cancer Institutes represented a modeled 15% of revenue and focus on complex surveillance, hereditary-risk counselling and interpretation of unusual findings. Specialist centres may provide MRI for carriers of pathogenic variants or individuals with a strong family history. They also help establish protocols for breast density, follow-up imaging and coordinated biopsy when clinically indicated. Revenue concentration reflects higher complexity per case rather than the largest screening population.
Validation and researchResearch Laboratories
Research Laboratories held a modeled 7% of test-related revenue through assay validation, translational screening studies and selected biomarker evaluations. Such laboratories may collaborate with hospitals to assess risk tools before broad clinical adoption. Investigational work is kept separate from routine population screening, and commercial forecasts do not assume that unapproved blood-based tests will displace mammography. This setting has a small base but can contribute to future technology development and evidence generation.
Each test is assigned to the facility performing or billing the service, even when a patient was referred by another provider. This prevents hospital-to-diagnostic-centre referrals from being counted as two separate screening transactions.
Breast Cancer Screening Tests Market Segmentation by End User
Report SegmentationBy End User
End User segments describe screening-eligible participant cohorts. Age and inherited risk influence invitation schedules, examination frequency and the probability of supplemental imaging, while country-specific guidelines determine eligibility.
Core recurring populationWomen Aged 50–74
Women aged 50–74 represented a modeled 57% of revenue because they form the core cohort of many established screening programmes. Australia actively invites women in this range, while England routinely invites women aged 50 up to their 71st birthday. Higher participation and repeated invitations support a stable test base, although screening intervals differ between countries.
Expanding eligibilityWomen Aged 40–49
Women aged 40–49 accounted for a modeled 22% and form an important incremental demand pool after the 2024 USPSTF recommendation. CDC data indicate lower recent mammography use in this age band than among women aged 50–74. Many first-time participants need education on recall probabilities, dense tissue and the reasons for screening before symptoms arise. Growth is contingent on insurer implementation, local scheduling capacity and patient preferences rather than guideline publication alone.
Intensive surveillance cohortHigh-Risk Younger Cohorts
High-Risk Younger Cohorts generated a modeled 14% of test revenue, despite representing a smaller patient population. People with strong hereditary susceptibility or previous chest radiation may begin MRI and mammography earlier than the general population under specialist guidance. Higher imaging intensity increases test value per participant but also requires genetic counselling, specialist capacity and individualized clinical decisions.
Additional eligible participantsOther Eligible Participants
Other Eligible Participants represented a modeled 7% and include older adults outside routine invitation ranges, selected symptomatic referrals initially assessed through screening channels and participants whose eligibility differs under national rules. England allows women over 71 to request screening, while U.S. evidence for routine screening after 75 remains insufficient for a general recommendation. Clinical decisions therefore depend on health status, preferences and local protocols, keeping this group smaller than the routinely invited population.
Age bands are mutually exclusive in the revenue allocation; high-risk younger participants are counted separately from routine-age cohorts, while older and exceptional eligibility cases are grouped under Other Eligible Participants.
Breast Cancer Screening Tests Market Segmentation by Screening Method
Report SegmentationBy Screening Method
Screening Method tracks the route by which an eligible person receives testing. Organized programmes generate recurring invitations, opportunistic testing occurs during routine care and risk-directed pathways follow individualized assessment.
Largest programme routeOrganized Population Screening
Organized Population Screening represented a modeled 58% of revenue. Public invitation systems in England and Australia create regular cohorts, consistent protocols and centralized quality monitoring. England recorded 2.75 million invitations for its core 50-to-under-71 group in 2024–25, showing the scale of organized recall. Procurement in this channel favours reproducible imaging, service reliability and clear audit trails. Uptake campaigns can increase test volume without changing the frequency recommended for each eligible person.
Provider-led testingOpportunistic Screening
Opportunistic Screening accounted for a modeled 27% and covers examinations initiated during primary-care visits, private health checks or clinician consultations outside formal invitation systems. It is important in fragmented healthcare markets where national recall programmes are limited. Providers may offer flexible appointments, but quality and continuity vary unless images, results and follow-up recommendations are shared with the patient’s usual care team. Its share is expected to remain material in urban private healthcare networks.
Personalized surveillanceRisk-Directed Screening
Risk-Directed Screening represented a modeled 15% and is selected after hereditary, family-history or other validated risk assessment. ACR guidance supports earlier MRI for some high-risk women, while the FDA density notification rule has increased attention to individualized discussions. The category can include more intensive surveillance but does not assume that every dense-breast patient requires additional tests. Referral accuracy, insurance approval and capacity at specialist sites determine the practical scale of risk-directed activity.
A person enrolled in an organized programme is counted there even when a radiologist recommends follow-up imaging. Risk-directed classification applies only when individualized surveillance is the primary reason for the screening encounter.
Breast Cancer Screening Tests Market Regional Analysis
Geographic differences arise from programme maturity, reimbursement, density-reporting practices and radiology infrastructure. North America leads the defined revenue basket, while European public systems support consistent invitations and Asia-Pacific expands through local installations and targeted screening initiatives.
North America
Largest market - 42% of 2025 revenueNorth America held a modeled 42% of 2025 revenue in the scoped screening-test basket. The United States combines insurance-funded mammography, an extensive outpatient imaging network and a mature regulatory framework under the Mammography Quality Standards Act. Enforcement of standardized breast-density notices in September 2024 added a communication requirement that affects patient counselling and risk-based follow-up. Adoption of digital tomosynthesis, breast ultrasound and AI-assisted interpretation remains subject to clinical evidence and payer policy. Canada has provincially organized programmes with differences in invitation ages and supplementary imaging access, making its revenue mix less uniform than a single national screening schedule would suggest. Across both markets, workforce shortages and appointment backlogs can restrict throughput even when reimbursement supports testing.
Priority country signals
United States
Selected market signalThe USPSTF advised biennial mammography from age 40 through 74 in April 2024, while ACR guidance supports annual imaging and earlier risk assessment for selected high-risk groups. CDC survey analysis found 80.0% of women aged 50–74 had current screening in 2023, compared with 62.1% of women aged 40–49 who had mammography within two years. These figures point to a participation opportunity, particularly for first-time screening. AI vendors target workflow efficiency, but radiologists remain responsible for final interpretation and appropriate follow-up.
Source: CDC.
Canada
Selected market signalProvincial screening programmes determine invitation ages, screening intervals and access to supplemental modalities. This creates a varied market for radiology providers and equipment suppliers despite a common emphasis on early detection. Publicly funded mammography is the primary routine modality, while higher-risk patients may receive specialist surveillance. Vendors must address provincial procurement and integration requirements rather than assuming that a single national commercial arrangement covers the country. Differences in programme organization also complicate direct comparisons of participation and revenue with the United States.
Source: WHO.
Europe
Established programmes - Public procurement and density protocolsEurope has mature organized screening in many countries, but age eligibility, intervals and the role of supplemental modalities differ by national policy. England provides an instructive benchmark: 71.8% of eligible women had current screening by March 2025, and its programme detected 19,291 cancers in 2024–25. European providers purchase digital mammography systems through competitive tenders, often balancing image quality with maintenance cost and reader availability. The growing use of AI for double-reading assistance is visible in Spain, where ScreenPoint Medical announced a regional Transpara deployment in 2025. Strong public-sector oversight creates a demanding evidence environment for vendors, and software buyers must demonstrate integration and clinical value rather than rely on standalone accuracy claims.
Priority country signals
United Kingdom
Selected market signalThe NHS screened 2.15 million women aged 45 and older during 2024–25 and recorded a 70.6% invitation uptake rate in its core age band. Routine invitations are issued from age 50 until the 71st birthday, generally every three years. A February 2025 awareness campaign targeted first-time non-attendance, while digital reminders and booking tools aim to improve participation. The commercial emphasis is on reliable programme delivery, image-reading capacity and avoiding unnecessary repeat visits rather than expanding private test prices.
Source: NHS England Digital.
Spain
Selected market signalThe regional health service of Castilla y Le - n announced a partnership with ScreenPoint Medical in September 2025 for Transpara breast AI across 15–17 screening centres. The region offers mammography screening to women aged 45–74, making radiologist workload and consistency important procurement considerations. The agreement illustrates how regional public purchasers can adopt AI while retaining organized programme governance. Expansion elsewhere depends on validated performance in local populations, interoperability and transparent monitoring of recalls and cancer detection.
Source: ScreenPoint Medical.
Asia-Pacific
Access expansion - Local installations and screening capacityAsia-Pacific combines high-income screening systems with populous countries where coverage remains uneven. Australia operates a government-funded programme that actively invites women aged 50–74, while Japan relies on municipal and employer-based pathways with different participation patterns. India and China have large unmet screening needs, but budgets, travel distance and the availability of trained radiographers limit routine mammography access. Fujifilm installations in Nizamabad and Mumbai demonstrate growing private-sector interest in compact, AI-assisted mammography platforms. IARC added validated cancer screening data from twelve Asian countries to CanScreen5 in September 2025, providing programme managers with better benchmarking tools. Regional value growth depends on converting equipment installations into sustained screening and follow-up activity, not simply increasing the number of scanners sold.
Priority country signals
India
Selected market signalFujifilm installed AMULET Innovality at a Nizamabad diagnostic centre in September 2025 and AMULET SOPHINITY at a Mumbai facility in June 2026. The company linked its investments to improving early detection and extending imaging capabilities beyond large metropolitan hospitals. Public screening infrastructure remains heterogeneous, so local centres need reliable referral pathways for suspicious results. The operational challenge is to pair equipment access with trained staff, patient awareness and affordable follow-up examinations.
Source: Fujifilm.
Australia
Selected market signalBreastScreen Australia offers free mammography every two years to women over 40 and actively invites those aged 50–74. The national programme provides a stable base for repeat imaging and supports consistent quality oversight. Remote populations can face greater travel burdens, creating demand for mobile services and dependable equipment maintenance. Participation rates, rather than headline cancer incidence alone, influence the number of tests delivered in each jurisdiction and the ability to detect disease at an earlier stage.
Source: Australian Government.
Latin America
Emerging programmes - Private and public delivery coexistLatin American screening is shaped by uneven access to imaging, variable insurance coverage and the concentration of specialist services in major cities. Brazil has a large breast cancer burden and both public and private diagnostic providers, but equipment availability does not guarantee timely diagnosis after a positive screen. Urban private centres are better positioned to introduce tomosynthesis and software assistance, while public systems prioritize broader coverage and basic quality assurance. The defined test basket grows when screening participation increases and follow-up pathways improve. Import costs, maintenance contracts and local currency movements can delay procurement of advanced modalities. Regional forecasts therefore assume gradual service expansion rather than a uniform shift to premium imaging technology across all countries.
Priority country signals
Brazil
Selected market signalBrazil is a priority market because its population size supports extensive screening needs, yet regional differences in healthcare infrastructure remain pronounced. Private diagnostic networks in large cities can adopt digital tomosynthesis and image-reading software, while public facilities may face longer replacement cycles. Early detection initiatives require patient outreach, image quality controls and referral coordination to prevent delays between a suspicious screen and diagnostic assessment. Growth in the modeled testing basket reflects broader participation rather than an assumption that all facilities will purchase the most expensive available equipment.
Source: IARC.
Middle East & Africa
Capacity-building region - Uneven access to imagingMiddle East & Africa is the smallest modeled regional market because access to organized mammography varies sharply across health systems. Gulf states support private hospital imaging and preventive check-ups, while many African communities depend on clinical assessment and referral to distant radiology facilities. The WHO Global Breast Cancer Initiative emphasizes early detection, timely diagnosis and comprehensive management as linked components of care. This framework is particularly relevant where investing in a screening unit without pathology and treatment capacity would yield limited benefits. Purchasers must account for radiographer training, electricity reliability, maintenance support and culturally appropriate outreach. Test-related revenue can expand through targeted programmes, but the regional growth path is constrained by workforce and financing limitations rather than the availability of new software alone.
Priority country signals
United Arab Emirates
Selected market signalThe UAE has an established private hospital and imaging sector that can adopt digital mammography and selected supplemental MRI or ultrasound for higher-risk patients. Screening access is strongest in major urban centres, while programme design and insurer benefits influence how often asymptomatic women are tested. Radiology providers must distinguish preventive mammograms from diagnostic workups and use consistent reporting standards. Over the forecast period, targeted outreach and specialist risk assessment offer more dependable growth than broad replacement of routine mammography with emerging blood-based assays.
Source: WHO.
Competitive Landscape
The supplier landscape spans mammography hardware, interpretation software, hereditary risk assessment and adjunct imaging. Hologic, Siemens Healthineers, GE HealthCare and Fujifilm compete on acquisition platforms, while ScreenPoint Medical and iCAD specialize in software-assisted review. Competition cannot be assessed from a single audited market-share table because public company disclosures typically combine broader imaging or diagnostics businesses.
Mammography platformsHologic and GE HealthCare
Hologic markets three-dimensional mammography and Genius AI Detection PRO, recognized in May 2025. GE HealthCare offers Pristina Via, contrast-enhanced mammography and automated breast ultrasound, with AI-supported Pristina reconstruction authorized in November 2025. Both suppliers focus on workflow, detection performance and radiology-system integration rather than on a stand-alone test cartridge.
Imaging system breadthSiemens Healthineers and Fujifilm
Siemens Healthineers expanded the MAMMOMAT B.brilliant portfolio with contrast-enhanced imaging and biopsy functions in December 2025. Fujifilm supplies AMULET systems and reported installations in Indian diagnostic facilities during 2025–2026. Their commercial propositions combine image quality, ergonomic positioning and service support across different facility sizes.
AI detection specialistsScreenPoint Medical and iCAD
ScreenPoint Medical markets Transpara Detection, Density and Temporal Comparison, while iCAD supplies ProFound AI for digital breast tomosynthesis and related breast health workflows. Regional deployment and integration agreements show growing demand for software adjuncts, but each tool requires appropriate validation and clinician oversight.
Risk and supplemental imagingMyriad Genetics, Koios, Philips and Planmed
Myriad provides hereditary risk assessment; Koios develops AI-supported breast ultrasound interpretation; Philips offers MRI reconstruction technology used in broader imaging workflows; and Planmed supplies Clarity digital mammography systems. These companies address distinct points in the screening pathway and should not be treated as interchangeable providers of population mammography tests.
Hospitals and outpatient centres apply different criteria when evaluating breast imaging purchases. Large hospital groups emphasize integration with picture archiving, radiology reporting, service contracts and patient throughput; small diagnostic centres place greater weight on installation footprint and predictable maintenance. AI software suppliers must establish compatibility with existing imaging systems, demonstrate performance across breast densities and address cybersecurity and data governance. A vendor with a strong product portfolio does not automatically have an equivalent share of the publisher-defined testing basket, especially when revenue includes unrelated radiology equipment.
Partnerships between software specialists and imaging companies are becoming more visible. iCAD announced a Microsoft network integration in April 2025 and a Koios ultrasound partnership in February 2025, illustrating the shift toward connected interpretation tools. ScreenPoint Medical signed a Spanish public-sector deployment during September 2025. Commercial differentiation through 2034 will depend on clinical evidence, workflow savings and follow-up quality, with risk assessment and patient communications offering additional routes for specialist suppliers.
Key Companies Profiled
- Hologic, Inc.
- GE HealthCare Technologies Inc.
- Siemens Healthineers AG
- FUJIFILM Holdings Corporation
- Planmed Oy
- ScreenPoint Medical B.V.
- iCAD, Inc.
- Myriad Genetics, Inc.
- Koios Medical, Inc.
- Koninklijke Philips N.V.
Recent Developments in the Breast Cancer Screening Tests Market
June 2026: Fujifilm India announced the first installation of its AI-assisted AMULET SOPHINITY digital mammography system at NM Medical in Mumbai. The platform includes a 50-micrometre detector, tomosynthesis acquisition and positioning assistance intended to support image quality and patient comfort. The installation demonstrates demand for advanced breast imaging in private outpatient centres. Source
December 2025: Siemens Healthineers introduced expanded contrast-enhanced mammography and biopsy capabilities for MAMMOMAT B.brilliant at RSNA 2025. The announcement described new reconstruction functionality for dense tissue and options to perform contrast-guided assessment without changing modalities, potentially reducing transfers between imaging rooms. Product availability varies by jurisdiction and by the system configuration approved for each facility. Source
November 2025: GE HealthCare announced FDA premarket authorization for Pristina Recon DL, an AI-supported three-dimensional mammography reconstruction application. The company described sharper image details and fewer artifacts as intended clinical workflow benefits. The authorization extends a product platform already used for breast screening and diagnostic assessment, with prospective performance evaluation remaining important at the point of care. Source
September 2025: ScreenPoint Medical announced an agreement with the Castilla y Le - n health service in Spain to deploy Transpara Breast AI across roughly 15–17 screening centres. The arrangement connects AI-supported interpretation with an established regional public mammography programme serving women aged 45–74. Implementation will depend on local workflow integration and quality monitoring. Source
September 2025: Fujifilm India installed its AMULET Innovality full-field digital mammography system at Vishwam Diagnostics in Nizamabad. The supplier highlighted low-dose acquisition and dense-breast image visualization as design objectives. The project broadens access to modern mammography outside India’s largest metropolitan radiology hubs, where service and maintenance support determine ongoing screening capacity. Source
April 2025: iCAD announced a collaboration with Microsoft to make its ProFound AI Breast Health Suite available through the Precision Imaging Network. The planned integration connects AI interpretation tools with radiology reporting workflows. It follows the FDA clearance of ProFound Detection Version 4.0 for digital breast tomosynthesis in November 2024. Source
Market Outlook, 2026–2034
The publisher-based breast cancer screening tests market is forecast to increase from USD 48.66 million in 2026 to USD 60.93 million by 2034, equivalent to 2.9% CAGR. Growth is linked to recurring screening demand and targeted technology upgrades rather than a wholesale replacement of routine mammography.
| Forecast variable | 2025–2026 baseline | Expected influence through 2034 |
|---|
| Age eligibility | USPSTF 40–74 biennial recommendation | Gradual expansion of first-time participation |
| Participation | England 71.8% coverage in March 2025 | Reminders and accessible appointments lift completed tests |
| Density communication | FDA notification rules enforced September 2024 | More individualized risk conversations and referrals |
| Imaging technology | Digital tomosynthesis and AI reading tools | Selective mix upgrade within constrained budgets |
| Regional capacity | Uneven radiographer and follow-up availability | Infrastructure limits adoption in lower-resource markets |
| Clinical evidence | Supplemental modalities remain risk-dependent | Validation determines reimbursement and procurement |
North America is expected to retain the largest revenue share because screening guidelines, reimbursement and established radiology capacity support repeat examinations. Its growth rate should remain moderate as a substantial portion of the eligible population already participates. Europe will prioritize participation and programme efficiency, while Asia-Pacific has greater headroom for expanding physical access through diagnostic centres and organized initiatives. Revenue allocation reflects test-related commercial activity rather than a direct conversion of cancer incidence into sales.
The strongest technology opportunities involve improved tomosynthesis acquisition, shorter examination workflows and AI assistance that helps radiologists focus on suspicious findings. These tools may raise the value of selected screening encounters, but clinical validation and local procurement rules limit their immediate penetration. Genetic risk assessment and MRI surveillance expand selectively for higher-risk cohorts; they are not substitutes for routine population mammography. Providers will continue to evaluate recall rates, interval cancers, patient experience and total cost per completed examination.
Downside risks include radiologist shortages, delays in public equipment replacement, low attendance after first invitations and concerns about false positives or overdiagnosis. The 2024 FDA breast-density rules improve information access but do not themselves establish universal coverage for supplemental imaging. Upside could arise from effective outreach, stronger data systems and integration of AI with existing scanners rather than expensive fleet replacement. Countries with limited pathology and treatment access must strengthen the full diagnostic pathway before screening volume can generate meaningful health benefits.
Competitive positioning will favour suppliers that support dependable imaging, secure data exchange and measurable workflow improvements. Public programmes are likely to remain cost-sensitive, while private diagnostic chains may adopt newer equipment earlier where patient demand and financing permit. The forecast assumes continued use of mammography as the population-screening standard through 2034, with adjunct ultrasound, MRI and hereditary risk tools selected according to clinical need. The USD 60.93 million endpoint describes the publisher-scoped testing basket and must not be compared directly with global capital equipment sales.
Report Coverage
Coverage spans publisher-scoped screening tests, clinical access routes, priority participants and technologies used in preventive breast imaging.
Market Sizing2025 base value, 2026 estimate and 2034 forecast with endpoint-derived annual growth.
Test SegmentationImaging, genetic, laboratory and physical examination tests without double-counted transactions.
Facility ApplicationsHospitals, diagnostic centres, cancer institutes and research laboratories.
Patient and Method MixRoutine-age, younger and high-risk cohorts; organized, opportunistic and risk-directed routes.
Regional AssessmentFive geographic regions with country-level programme, capacity and vendor signals.
Supplier and Policy ReviewImaging platforms, AI adjuncts, risk tests, density reporting and procurement developments.
Frequently Asked Questions
How large is the breast cancer screening tests market?
The publisher-scoped market was valued at USD 47.3 million in 2025 and is estimated at USD 48.66 million in 2026. The 2034 forecast is USD 60.93 million. These figures describe a defined screening-test basket, not total global expenditure on mammography equipment or public radiology services.
What CAGR is projected for breast cancer screening tests?
Revenue is projected to grow at a 2.9% compound annual rate between 2026 and 2034. The rate follows the publisher’s 2024 and 2031 monetary endpoints, with steady screening participation and selective adoption of supplemental technologies supporting growth.
Which breast screening test is used most often?
Mammography is the established population-screening modality for most average-risk women. Digital breast tomosynthesis can provide additional tissue planes, while ultrasound and MRI are used selectively. The Type revenue model places imaging tests first with a 64% share of the scoped basket in 2025.
At what age should women begin routine mammography?
The USPSTF recommends screening every two years from ages 40 through 74 for average-risk women in the United States. England typically invites women from age 50 until 71, and Australia actively invites ages 50–74. Individualized screening schedules may begin earlier for people with documented hereditary or other elevated risks.
Which region leads the breast cancer screening tests market?
North America held a modeled 42% share of the 2025 publisher-defined market. Its position reflects established reimbursement, broad radiology infrastructure and routine mammography participation. Europe follows with organized programmes, while Asia-Pacific has substantial capacity-expansion opportunities.
Does dense breast tissue require additional screening?
Dense tissue can reduce mammographic sensitivity and is now disclosed under U.S. federal reporting rules. Supplemental MRI or ultrasound may be considered after individualized risk assessment, but a density notice alone does not establish a universal requirement for extra imaging.
Can genetic tests diagnose breast cancer during screening?
Hereditary panels assess susceptibility and help identify people who may benefit from earlier or more intensive surveillance. They do not show that a current breast tumour is present. Imaging and diagnostic follow-up remain necessary when symptoms or suspicious screening findings arise.
How is artificial intelligence used in mammography?
AI software can flag suspicious image regions, assess density or support reading workflows. ScreenPoint Medical and iCAD provide commercial tools, while imaging suppliers integrate reconstruction assistance. A qualified clinician remains responsible for interpreting results and determining appropriate follow-up.
What limits screening participation in emerging markets?
Common barriers include travel distance, limited radiology capacity, equipment maintenance, cost and insufficient diagnostic follow-up after an abnormal result. Public education can improve demand, but sustained benefit requires coordinated imaging, pathology and treatment pathways across multiple care facilities.
Who are the main companies in breast screening technology?
Relevant suppliers include Hologic, GE HealthCare, Siemens Healthineers, Fujifilm, Planmed, ScreenPoint Medical, iCAD, Myriad Genetics, Koios Medical and Philips. Their products span imaging systems, interpretation software, hereditary risk assessment and supplemental imaging, with different reimbursement and clinical validation requirements.
What is the outlook for breast screening through 2034?
The market is forecast to reach USD 60.93 million within the defined revenue boundary. Expansion is expected to remain gradual as routine mammography programmes mature, with selective contributions from tomosynthesis, AI interpretation, genetic risk assessment and improved screening participation.
Research Sources & Evidence Base
View research sources used for this overview
- IARC. Breast Cancer Awareness Month: global 2024 burden, October 2026.
- WHO. Global Breast Cancer Initiative, 2026.
- USPSTF. Final recommendation on breast screening, April 2024.
- FDA. MQSA breast density reporting requirements, September 2024.
- CDC. Use of Cancer Screening Tests, United States 2023, 2025.
- NHS England Digital. Breast screening programme 2024–25 statistics, 2025.
- NHS England. First breast screening awareness campaign, February 2025.
- Australian Government. BreastScreen Australia programme, 2026.
- American College of Radiology. High-risk screening guidance, May 2023.
- IARC. CanScreen5 data from twelve Asian countries, September 2025.
- Hologic. Genius AI Detection PRO technology recognition, May 2025.
- GE HealthCare. Breast imaging portfolio at SBI 2025, April 2025.
- GE HealthCare. Pristina Recon DL authorization, November 2025.
- Siemens Healthineers. MAMMOMAT B.brilliant expanded capabilities, December 2025.
- Fujifilm. AMULET Innovality installed in Nizamabad, September 2025.
- Fujifilm. AMULET SOPHINITY installed in Mumbai, June 2026.
- ScreenPoint Medical. Transpara deployed in Castilla y Le - n, September 2025.
- ScreenPoint Medical. Transpara reader study summary, July 2025.
- iCAD. Microsoft Precision Imaging Network collaboration, April 2025.
- iCAD and Koios. Multimodal breast imaging partnership, February 2025.
- Myriad Genetics. Expanded MyRisk hereditary cancer panel, November 2025.
- Planmed. Clarity digital mammography product range, 2026.
- Philips. SmartSpeed Precise FDA 510(k) clearance, July 2025.